Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 852, Issue 1-2, 2007, Pages 92-100

  Wang, Ganfeng ^a   Hsieh, Yunsheng ^a   Cheng, Kuo Chi ^a   Morrison, Richard A ^a   Venkatraman, Srikanth ^a   Njoroge, F George ^a   Heimark, Larry ^a   Korfmacher, Walter A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diastereomers; LC MS MS; Plasma; SCH 503034; UPLC

Indexed keywords

DIASTEREOMERS; UPLC;

BODY FLUIDS; LIQUID CHROMATOGRAPHY; LIVING SYSTEMS STUDIES; MAMMALS; MASS SPECTROMETRY; PROTEINS; STEREOCHEMISTRY;

ISOMERS;

ACETONITRILE; METHANOL; SCH 503034; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; MACACA FASCICULARIS; MALE; PROLINE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 34249702447     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.12.038     Document Type: Article

References (20)

1. FDA's Policy Statement for the Development of Stereoisomeric Drugs, www.fda.gov/cder/guidence/stereo.htm.
2. Korfmacher W.A. Curr. Opinion Drug Discovery Dev. 6 (2003) 481
3. Korfmacher W.A. Drug Discovery Today 10 (2005) 1357
4. Jamali F. Pharmacology 32 (1992) 930
5. Maier N., Franco P., and Lindner W. J. Chromatgr. A 906 (2001) 3
6. Hsieh Y., and Wang G. Am. Pharm. Rev. 7 (2004) 88
7. Chen J., Hsieh Y., and Korfmacher W.A. J. Chromatgr. B 820 (2005) 1
8. Hsieh Y., Favreau L., Schwerdt J., and Cheng K. J. Pharm. Biomed. Anal. 24 (2006) 799
9. Hsieh Y., Favreau L., Cheng K., and Chen J. Rapid Commun. Mass Spectrom. 19 (2005) 3037
10. Sherma J. J. AOAC Int. 88 (2005) 63
11. Wren S.A. J. Pharm. Biomed. Anal. 38 (2005) 337
12. Castro-Perez J., Plumb R., Granger J.H., Beattie I., Joncour K., and Wright A. Rapid Commun. Mass Spectrom. 19 (2005) 843
13. Wilson I.D., Nicholson J.K., Castro-Perez J., Granger J.H., Johnson K.A., Smith B.W., and Plumb R.S. J. Proteome Res. 4 (2005) 591
14. Petritis K., Brussaux S., Guenu S., Elfakir C., and Dreux M. J. Chromatgr. A 975 (2002) 173
15. Wybraniec S., and Mizrahi Y.J. J. Chromatgr. A 1029 (2004) 97
16. Piraud M., Vianey-Saban C., Petritis K., et al. Rapid Commun. Mass Spectrom. 19 (2005) 1578
17. Mei H. In: Korfmacher W.A. (Ed). Using Mass Spectrometry for Drug Metabolism Studies (2005), CRC Press, Boca Raton, FL 103
18. Plumb R.S., Dear G.J., Higton D.N., Mallett D.M., Pleasance S., and Biddlecombe R.A. Xenobiotica 31 (2001) 599
19. King R., Bonfiglio R., Fernandez-Metzler C., Miller-Stein C., and Olah T.J. Am. Soc. Mass Spectrom. 11 (2000) 942
20. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 75 (2003) 3019